Peripartum Cardiomyopathy: From Pathophysiology to Management

Front-Matter_2021_Peripartum-Cardiomyopathy
	Front Matter
Copyright_2021_Peripartum-Cardiomyopathy
	Copyright
Contributors_2021_Peripartum-Cardiomyopathy
	Contributors
Preface_2021_Peripartum-Cardiomyopathy
	Preface
Acknowledgments_2021_Peripartum-Cardiomyopathy
	Acknowledgments
Foreword_2021_Peripartum-Cardiomyopathy
	Foreword
Chapter-1---Etiology-and-pathophysiology_2021_Peripartum-Cardiomyopathy
	Etiology and pathophysiology
		Genetics of PPCM
		References
Chapter-2---How-to-diagnose-the-condition_2021_Peripartum-Cardiomyopathy
	How to diagnose the condition
		Clinical presentation
		Investigations
			Electrocardiography
			Blood tests and biomarkers
			Chest radiography
			Transthoracic echocardiography
			Cardiac magnetic resonance imaging
			Genetic testing
		Summary
		References
Chapter-3---Risk-stratification-in-patients-newly-diagn_2021_Peripartum-Card
	Risk stratification in patients newly diagnosed with peripartum cardiomyopathy
		Patient characteristics
			Age
			Medical history
			Onset and time of diagnosis
		Hemodynamic parameters
		ECG
		Concomitant hypertension
		Predictors of mortality and morbidity
		Predictors of LV function recovery
		Concomitant right ventricular dysfunction at diagnosis
		Magnetic resonance imaging (MRI)
		Other factors associated with lack of LV function recovery (ethnicity, biomarkers)
			Ethnicity
			Biomarkers
		Genetic predictors
			Summary
		References
Chapter-4---How-to-manage-a-woman-presenting-with-_2021_Peripartum-Cardiomyo
	How to manage a woman presenting with acute PPCM?
		Introduction
		Clinical presentation and evaluation of acute PPCM
		Management of acute PPCM presenting with systemic congestion without cardiopulmonary distress
		Initial management of acute PPCM with cardiopulmonary distress or hemodynamic instability
		Advanced management of severe acute PPCM
		References
Chapter-5---What-needs-to-be-known-about-longer-term-m_2021_Peripartum-Cardi
	What needs to be known about longer-term management and prognosis?
		Management
			Beta-blocker
			Angiotensin-converting enzyme inhibitor
			Angiotensin receptor blocker
			Angiotensin receptor neprilysin inhibitor
			Mineralocorticoid receptor antagonist
			Ivabradine
			Diuretics
			Cardiac glycosides
			Vasodilators
			Nitrates
			Anticoagulation
			Heparin and synthetic pentasaccharides
			Long-term therapy
			General approach for follow-up
			Devices
				Wearable cardioverter-defibrillator
				Implantable cardioverter-defibrillator and cardiac resynchronization therapy
				Left ventricular assist device and heart transplantation
				Other implantable electronic devices
		Prognosis
			Recovery of left ventricular function
				Recovery at 6  months
				Recovery beyond 6  months
			Mortality
			Predictors
				Clinical parameters and genetics
				Electrocardiogram
				Laboratory parameters
				Imaging
		References
Chapter-6---Is-a-subsequent-pregnancy-safe-_2021_Peripartum-Cardiomyopathy
	Is a subsequent pregnancy safe?
		Maternal risk during a subsequent pregnancy
		Fetal risk during a subsequent pregnancy
		A practical approach to a subsequent pregnancy
			Summary
		References
Chapter-7---How-to-advise-on-safe-delivery-and-best-cont_2021_Peripartum-Car
	How to advise on safe delivery and best contraception for patients with heart failure
		Anticoagulation
		Termination of pregnancy
		Mode of delivery
		Contraception
		Summary
		References
Chapter-8---What-can-be-learned-from-the-global-reg_2021_Peripartum-Cardiomy
	What can be learned from the global registry on PPCM?
		Background to the registry
		Methodology
			Challenges of setting up a biobank
			Other overall challenges
			Overall successes
		Key findings from the registry
		Lessons learned
		References
Chapter-9---Setting-up-a-clinical-service-for-PPC_2021_Peripartum-Cardiomyop
	Setting up a clinical service for PPCM in Iraq
		Introduction
		Peripartum cardiomyopathy in Iraq: What was known and how was dealing with?
		Challenges and barriers during setting a new PPCM service in Iraq
		Initiative for setting new PPCM service in Iraq
		Plan for setting up a clinical service for PPCM in Iraq: Questions and answers
		Impact of EORP-PPCM registry on the setting up a clinical service for PPCM in Iraq
		Exceptional data from the real daily practice about subsequent pregnancies in patients with PPCM
		Future plan for quality improvement of PPCM service in Iraq
		Lessons to learn and keys of success
		For the sake of history, messages to Prof. Karen Sliwa and ESC from Iraqi PPCM site
		References
Chapter-10---Electrocardiographic-assessment-and-manageme_2021_Peripartum-Ca
	Electrocardiographic assessment and management of arrhythmias in peripartum cardiomyopathy
		Introduction
		The 12‑lead electrocardiogram in PPCM
		Ambulatory ECG monitoring in PPCM
		Prevention and treatment of arrhythmias in PPCM
		Implantable and wearable cardioverter defibrillators in PPCM
		Conclusion
		Acknowledgments
		References
Chapter-11---Learning-from-the-peripartum-cardiomyopathy-in-_2021_Peripartum
	Learning from the peripartum cardiomyopathy in Nigeria (PEACE) registry: A multisite, contemporary PPCM registry in Nigeria
		Background
		Summary of the study protocol
		Clinical profile, incidence and risk factors of PPCM patients in Nigeria
		Mortality of PPCM patients in Nigeria
		Remodeling of cardiac chambers in PPCM patients in Nigeria
		Selenium supplementation trial in PPCM
		Relationship between serum selenium and ventricular dysfunction in apparently healthy pregnant women
		Conclusion
		References
Index_2021_Peripartum-Cardiomyopathy
	Index
		A
		B
		C
		D
		E
		F
		G
		H
		I
		K
		L
		M
		N
		O
		P
		Q
		R
		S
		T
		U
		V
		W